home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  May 28, 2024
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 461 active entries


7 Coach Road
Lexington, MA 02420-1101
United States of America, Massachusetts

Phone: 617-308-8200
Fax: 208-730-5966

Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


Smart Hydrogel(TM), is a novel,
proprietary synthetic material comprised of two FDA-approved polymers,
poly(acrylic acid) and Pluronic, each with a long history of
medical use. The polymers, which produce a water soluble
system, are bonded together. When warmed to body temperature, the
system produces a gel state.

Smart Hydrogel has a number of properties that together define its
uniqueness. Most notably, at low concentration of polymer, the
material undergoes a transition from a free-flowing liquid to
a solid gel as the temperature is raised from room to body
temperature. The reverse transition enables application of
drug in liquid form. When the gel reaches the desired body surface, it
solidifies, causing drug to be maintained in situ for hours.

The benefit of this feature is greater bioavailability of hydrophobic
or difficult to solubilize drugs using transmucosal delivery,
preferable to subcutaneous injection among the patient population.
Transmucosal modes addressed by the Company include esophageal,
nasal, vaginal and ophthalmic.

The Company has conducted a limited number of preclinical studies for
transmucosal drug delivery using Smart Hydrogel in three animal models:
rodents, rabbits and sheep. Nine drugs have been formulated with the
material and tested in vivo. Pilot testing in humans has been performed
under an Institutional Review Board (IRB).

The second major technology for drug delivery is Gel pHORCE(TM) for oral
administration. Orally delivered drugs represent half of the total market
and are the preferred method of delivery. The Company believes that the
Gel pHORCE technology can provide controlled drug delivery to the gastrointestinal
tract for local treatment or systemic absorption.

The Gel pHORCE system can be engineered for a specific kinetic profile.
The system allows for the initiation of drug release at a desired pH and
release rates that are independent of drug properties

Selected Categories:

Product Company   Service Company
- General
- General
- General
- Research
- Strategic
- Production
- Services

Last update of this entry: May 03, 2011

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.